Daniel F. Voytas Sells 4,666 Shares of Calyxt (CLXT) Stock

Calyxt (NASDAQ:CLXT) insider Daniel F. Voytas sold 4,666 shares of the company’s stock in a transaction on Friday, April 20th. The shares were sold at an average price of $16.87, for a total value of $78,715.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Daniel F. Voytas also recently made the following trade(s):

  • On Monday, April 9th, Daniel F. Voytas sold 4,083 shares of Calyxt stock. The shares were sold at an average price of $14.38, for a total value of $58,713.54.

CLXT opened at $15.98 on Thursday. Calyxt has a 12-month low of $9.26 and a 12-month high of $31.89. The company has a debt-to-equity ratio of 0.18, a current ratio of 13.52 and a quick ratio of 13.52.

Calyxt (NASDAQ:CLXT) last posted its quarterly earnings results on Tuesday, March 13th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.03). Calyxt had a negative return on equity of 75.53% and a negative net margin of 5,164.61%. The firm had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.10 million. research analysts forecast that Calyxt will post -1.31 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. bought a new position in shares of Calyxt during the 3rd quarter worth $358,000. Bank of New York Mellon Corp bought a new position in shares of Calyxt during the 3rd quarter worth $542,000. California State Teachers Retirement System bought a new position in shares of Calyxt during the 3rd quarter worth $323,000. American International Group Inc. bought a new position in shares of Calyxt during the 3rd quarter worth $133,000. Finally, BlackRock Inc. grew its position in shares of Calyxt by 102.8% during the 4th quarter. BlackRock Inc. now owns 740,010 shares of the company’s stock worth $16,302,000 after buying an additional 375,137 shares in the last quarter. 22.06% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have commented on the company. Zacks Investment Research downgraded Calyxt from a “hold” rating to a “sell” rating in a research report on Friday, March 23rd. Jefferies Group reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Calyxt in a research report on Thursday, March 22nd. Finally, ValuEngine raised Calyxt from a “sell” rating to a “hold” rating in a research report on Wednesday, March 14th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $29.05.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by WKRB News and is owned by of WKRB News. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.wkrb13.com/2018/04/26/daniel-f-voytas-sells-4666-shares-of-calyxt-clxt-stock.html.

About Calyxt

Calyxt, Inc, a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for plants in the United States. It engages in the development of high oleic soybeans, high fiber wheat, herbicide tolerant wheat, powdery mildew resistant wheat, enhanced oil composition and herbicide tolerant canola, enhanced quality and herbicide tolerant alfalfa, late blight resistant potatoes, and cold storable/reduced browning potatoes, as well as enhanced protein composition, drought tolerant, herbicide tolerant, and enhanced yield soybeans.

Insider Buying and Selling by Quarter for Calyxt (NASDAQ:CLXT)

Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply